Aime Castillo Mazantini
Family Medicine · Woodland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Aime Castillo Mazantini’s office at (530) 405-2800 to ask if they take your plan before you enroll.
California Medical Board record
Licence A167201 · Current
Licensed to practise in California · since 2019 · expires 2027-12-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Family Medicine - Family Medicine
Medicaid work
$351,642 in 2024
Medicaid paid $351,642 for 4,846 billed services this clinician did in 2024, up to 158 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,609 | $337,548 |
| Short return visit (20+ min) | 1,484 | $6,056 |
| Return visit (30+ min) | 660 | $2,734 |
| Annual alcohol misuse screening, 5 to 15 minutes | 232 | $2,163 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 101 | $872 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 61 | $770 |
| Short return visit | 263 | $721 |
| Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 77 | $562 |
| Screening test, pure tone, air only | 79 | $90 |
| Hemoglobin A1C level | 95 | $85 |
| HEMOGLOBIN | 75 | $27 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 24 | $9 |
| 2024 | 4,846 | 15 | 158 | $351,642 |
| 2023 | 5,826 | 14 | 166 | $331,954 |
| 2022 | 3,537 | 10 | 109 | $198,924 |
| 2021 | 1,867 | 8 | 125 | $127,972 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 1,771 | $314,661 |
| Short return visit (20+ min) | 1,782 | $7,545 |
| Return visit (30+ min) | 975 | $4,240 |
| Annual alcohol misuse screening, 5 to 15 minutes | 276 | $2,169 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 114 | $1,502 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 113 | $847 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 49 | $339 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 48 | $225 |
| Short return visit | 104 | $214 |
| Screening test, pure tone, air only | 102 | $134 |
| HEMOGLOBIN | 118 | $60 |
| Hemoglobin A1C level | 28 | $17 |
2022
| Clinic visit/encounter, all-inclusive | 1,106 | $186,248 |
| Short return visit (20+ min) | 1,066 | $5,987 |
| Return visit (30+ min) | 644 | $2,685 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 112 | $1,264 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 113 | $1,249 |
| Short return visit | 341 | $750 |
| Annual alcohol misuse screening, 5 to 15 minutes | 87 | $676 |
| Haemophilus influenzae type b vaccine, PRP-OMP conjugate | 18 | $63 |
| HEMOGLOBIN | 15 | $2 |
| EMERGENCY DEPT VISIT LOW MDM | 35 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 711 | $123,151 |
| Return visit (30+ min) | 360 | $1,881 |
| Annual alcohol misuse screening, 5 to 15 minutes | 149 | $1,097 |
| Short return visit (20+ min) | 356 | $957 |
| Short return visit | 217 | $558 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 23 | $328 |
| EMERGENCY DEPT VISIT LOW MDM | 36 | $0 |
| Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 15 | $0 |
Drugs they prescribed that Part D paid
$261,572
Pharmacies billed $261,572 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (89 of 1,995) in 2024. Above the middle of the specialty; the typical family practice clinician is at 2%.
1,703 generic and 273 brand-name prescriptions · $261,572 in drug cost · 27 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trulicity | 32 | $42,625 | $1,332 |
| Jardiance | 27 | $31,424 | $1,164 |
| Ozempic | 29 | $27,482 | $948 |
| Basaglar Kwikpen U-100 | 38 | $14,725 | $388 |
| Lantus Solostar | 23 | $2,180 | $95 |
See all 45 drugs
| Trulicity | 32 | $42,625 | $1,332 |
| Jardiance | 27 | $31,424 | $1,164 |
| Ozempic | 29 | $27,482 | $948 |
| Basaglar Kwikpen U-100 | 38 | $14,725 | $388 |
| Lantus Solostar | 23 | $2,180 | $95 |
| Hydroxyzine | 22 | $1,090 | $50 |
| Gabapentin | 84 | $900 | $11 |
| Hydrocodone-Acetaminophen | 34 | $723 | $21 |
| Albuterol Sulfate Hfa | 19 | $666 | $35 |
| Hydralazine | 40 | $629 | $16 |
| Atorvastatin | 135 | $611 | $5 |
| Buprenorphine-Naloxone | 12 | $573 | $48 |
| Levothyroxine | 58 | $530 | $9 |
| Metformin | 81 | $522 | $6 |
| Tizanidine | 14 | $495 | $35 |
| Amitriptyline | 16 | $488 | $31 |
| Duloxetine | 29 | $473 | $16 |
| Lisinopril | 72 | $458 | $6 |
| Amlodipine Besylate | 72 | $413 | $6 |
| Omeprazole | 47 | $398 | $8 |
| Simvastatin | 35 | $371 | $11 |
| Metoprolol | 28 | $363 | $13 |
| Losartan | 49 | $322 | $7 |
| Diclofenac | 18 | $299 | $17 |
| Trazodone | 24 | $275 | $11 |
| Metoprolol | 46 | $272 | $6 |
| Losartan-Hydrochlorothiazide | 23 | $268 | $12 |
| Oxycodone | 31 | $256 | $8 |
| Tamsulosin | 22 | $239 | $11 |
| Nifedipine Er | 19 | $239 | $13 |
| Hydrochlorothiazide | 66 | $228 | $3 |
| Fluoxetine | 12 | $220 | $18 |
| Latanoprost | 15 | $157 | $10 |
| Ibuprofen | 32 | $157 | $5 |
| Furosemide | 43 | $134 | $3 |
| Fluticasone Propionate | 18 | $132 | $7 |
| Finasteride | 14 | $104 | $7 |
| Baclofen | 14 | $96 | $7 |
| Lisinopril-Hydrochlorothiazide | 21 | $90 | $4 |
| Oxycodone-Acetaminophen | 12 | $80 | $7 |
| Carvedilol | 18 | $56 | $3 |
| Naproxen | 13 | $51 | $4 |
| Glipizide | 23 | $41 | $2 |
| Sertraline | 22 | $39 | $2 |
| Lorazepam | 14 | $24 | $2 |
Year by year
| 2024 | 1,995 | 160 | 5% (89) | 14% | $261,572 |
| 2023 | 1,308 | 136 | 5% (61) | None | $199,876 |
| 2022 | 606 | 64 | 6% (39) | None | $51,462 |
| 2021 | 285 | 94 | 5% (15) | None | $20,043 |
| 2020 | 265 | 58 | 5% (12) | None | $17,963 |
| 2019 | 58 | 29 | 0% (0) | 33% | $5,314 |
| 2018 | 99 | 37 | 0% (0) | 29% | $20,224 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 34 drugs
| Trulicity | 24 | $32,130 | $1,339 |
| Jardiance | 16 | $24,924 | $1,558 |
| Basaglar Kwikpen U-100 | 19 | $10,882 | $573 |
| Atorvastatin | 91 | $2,519 | $28 |
| Trazodone | 18 | $1,804 | $100 |
| Lisinopril | 59 | $1,661 | $28 |
| Gabapentin | 50 | $1,408 | $28 |
| Duloxetine | 23 | $1,301 | $57 |
| Hydrocodone-Acetaminophen | 44 | $1,211 | $28 |
| Diclofenac | 28 | $969 | $35 |
| Amlodipine Besylate | 46 | $951 | $21 |
| Omeprazole | 35 | $786 | $22 |
| Albuterol Sulfate Hfa | 21 | $779 | $37 |
| Metformin | 41 | $754 | $18 |
| Losartan | 24 | $683 | $28 |
| Sertraline | 21 | $625 | $30 |
| Tamsulosin | 16 | $617 | $39 |
| Levothyroxine | 30 | $572 | $19 |
| Pioglitazone | 12 | $525 | $44 |
| Simvastatin | 21 | $491 | $23 |
| Metoprolol | 16 | $450 | $28 |
| Nifedipine Er | 17 | $442 | $26 |
| Ropinirole | 14 | $412 | $29 |
| Hydrochlorothiazide | 36 | $330 | $9 |
| Ibuprofen | 27 | $307 | $11 |
| Fluticasone Propionate | 15 | $280 | $19 |
| Losartan-Hydrochlorothiazide | 11 | $278 | $25 |
| Oxycodone | 17 | $265 | $16 |
| Hydralazine | 15 | $240 | $16 |
| Furosemide | 31 | $204 | $7 |
| Metoprolol | 17 | $189 | $11 |
| Methimazole | 12 | $145 | $12 |
| Lorazepam | 12 | $89 | $7 |
| Glipizide | 15 | $84 | $6 |
2022: 12 drugs
| Gabapentin | 24 | $1,063 | $44 |
| Trazodone | 18 | $1,057 | $59 |
| Atorvastatin | 52 | $842 | $16 |
| Pioglitazone | 11 | $531 | $48 |
| Metformin | 25 | $454 | $18 |
| Lisinopril | 21 | $370 | $18 |
| Hydrocodone-Acetaminophen | 28 | $330 | $12 |
| Omeprazole | 13 | $304 | $23 |
| Amlodipine Besylate | 28 | $304 | $11 |
| Losartan | 14 | $303 | $22 |
| Hydrochlorothiazide | 32 | $199 | $6 |
| Ibuprofen | 15 | $144 | $10 |
2021: 4 drugs
| Gabapentin | 14 | $521 | $37 |
| Atorvastatin | 21 | $291 | $14 |
| Amlodipine Besylate | 18 | $180 | $10 |
| Lisinopril | 11 | $115 | $10 |
2020: 4 drugs
| Gabapentin | 13 | $225 | $17 |
| Famotidine | 20 | $180 | $9 |
| Atorvastatin | 14 | $173 | $12 |
| Lisinopril | 12 | $137 | $11 |
Money from drug and device companies
$36 in 2024
| 2024 | 2 | 2 | None | $36 |
| 2023 | 6 | 7 | None | $108 |
| 2022 | 5 | 7 | None | $96 |
| 2021 | 2 | 3 | None | $109 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $20 | 1 payment
|
| ViiV Healthcare | Dovato | $16 | 1 payment
|
See all 2 published payments
| ViiV Healthcare | Meals · 2024-05-31 | Dovato | $16 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2024-03-20 | Xifaxan | $20 |
See earlier years (2023, 2022, 2021)
2023: $108
| Merck Sharp & Dohme | Rotateq | $31 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $22 | 1 payment
|
| Teva Pharmaceuticals USA | Uzedy | $16 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $16 | 1 payment
|
| Cranial Technologies | Doc Band | $14 | 1 payment
|
| Organon | Nexplanon | $9 | 1 payment
|
2022: $96
| Merck Sharp & Dohme | Gardasil 9 | $40 | 3 payments
|
| Gilead Sciences | None | $22 | 1 payment
|
| Ultragenyx Pharmaceutical | None | $17 | 1 payment
|
| Janssen Pharmaceuticals | Invega Sustenna | $13 | 1 payment
|
| Organon | Nexplanon | $5 | 1 payment
|
2021: $109
| W. L. Gore & Associates | Gore Cardioform Septal Occluder | $76 | 1 payment
|
| Merck Sharp & Dohme | Januvia | $33 | 2 payments
|
Professional record
- NPI
- 1346622081
- Licence
- CA A167201California A167201: Current · expires 2027-12-31
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 215 W Beamer St, Woodland, CA, 95695
- NPI first listed
- 2015-06-18
- NPI last updated
- 2025-04-22
- NPI record certified
- 2025-04-22
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 975 Sereno Dr, Vallejo, CA, 94589